Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Àêóøåðñòâî è ãèíåêîëîãèÿ > Ïðîáëåìû âî âðåìÿ áåðåìåííîñòè

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 05.09.2006, 19:55
Àëåêñàíäðà Ø. Àëåêñàíäðà Ø. âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 05.09.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 35
Ñêàçàë(à) ñïàñèáî: 13
Àëåêñàíäðà Ø. *
Ãåìîñòàçèîãðàììà è ïðîãåñòåðîí ïðè áåðåìåííîñòè

Óâàæàåìûå âðà÷è!

Áîëüøàÿ ïðîñüáà ïîìî÷ü ìíå ñîõðàíèòü ïÿòóþ äîëãîæäàííóþ áåðåìåííîñòü!

Ìíå 32 ãîäà, ãèïåðïðîëàêòèíåìèÿ (ïîñòîÿííî ïðèíèìàëà áðîìêðèïòèí).

Ïðåäûäóùèå áåðåìåííîñòè:
1991 ãîä – âûêèäûø íà 5 íåäåëå, íå âûñêàáëèâàëè
2003 ãîä – âíåìàòî÷íàÿ ñïðàâà, ëàïàðàñêîïè÷åñêàÿ îïåðàöèÿ, óäàëåíèå òðóáû
2005 ãîä, ìàé – çàìåðøàÿ íà ñðîêå 7-8 íåäåëü, îáíàðóæèëè íà 11-îé. Äâà âûñêàáëèâàíèÿ (ïåðâîå ñäåëàíî íåóäà÷íî). Õðîìîñîìíûé àíàëèç – íàñëåäñòâåííîé ïàòîëîãèè, ñâÿçàííîé ñ õðîìîñîìíûìè àáåððàöèÿìè íå îáíàðóæåíî.
2005 ãîä, ñåíòÿáðü – âûêèäûø íà ñðîêå 7 íåäåëü, íå âûñêàáëèâàëè, âñå âûøëî ñàìî. Ñîáñòâåííî è ÓÇÈ â òîò ðàç íè÷åãî íå îáíàðóæèëî – áåðåìåííîñòü îïðåäåëèëè ïî ÕÃ× (ÕÃ× áûëî 1094 ïðè äâóõíåäåëüíîé çàäåðæêå).

Ïîñëå ýòîãî îáñëåäîâàëàñü.
1. Öèòîãåíåòèêà: 46ÕÕ. Íà 100 êëåòîê îáíàðóæåíî 2%êëåòîê ñ àáåððàöèÿìè õðîìîñîì, ÷àñòîòà ðàçðûâîâ õðîìàòèä íà êëåòêó – 0,02.
2. Èììóíîëîãèÿ áåç ñåðüåçíûõ îòêëîíåíèé
3. Ãîìîöèñòåèí – 19,8 ìêã/ë (íîðìà 8-10)
4. Ãåìîñòàçèîãðàììà – ïîâûøåíî àêòèâèðîâàííîå âðåìÿ ðåêàëüöèôèêàöèè – 89,1 ñåê (íîðìà 50-70)
5. Àóòîàíòèòåëà â êðîâè â íîðìå
6. Ä-äèìåð 10 íã/ìë (íîðìà <248)
7. Àíòèòåëà ê ôàêòîðó ðîñòà íåðâîâ 0,6 (íîðìà 0,5-0,95)
8. Ïîëèìîðôèçì ãåíîâ öèòîêèíîâ – åñòü îäèí ïðîòèâîñïàëèòåëüíûé àëëåëü (ïîâûøåíèå ñåêðåöèè IL1a) - Ãåí IL1B, öèòîêèí IL1áåòà, ïîçèöèÿ ïîëèìîðôèçìà Ñ+3953Ò.
9. Àíàëèç íà âîë÷àíî÷íûé à/ê â íîðìå
10. Ãîðìîíû â íîðìå. (ïðîëàêòèí – íà ôîíå ïðèåìà áðîìêðèïòèíà).

Ñåé÷àñ ÿ áåðåìåííà ñíîâà, óæå 7 íåäåëü, èäåò 8-ÿ (ïîñëåäíèå ìåñÿ÷íûå 16.07.2006). Áåðåìåííîñòü íàñòóïèëà ñïîíòàííî. Ñ 11.08 â òå÷åíèå íåäåëè òÿíóëî æèâîò (êàê ïåðåä ìåñÿ÷íûìè). Êîðè÷íåâûå âûäåëåíèÿ áûëè 10-12.08. Äîìàøíèå òåñòû ïîëîæèòåëüíûå ñ 12.08. Ñ 19.08 ïîñòîÿííî èäóò ñêóäíûå êîðè÷íåâûå âûäåëåíèÿ (âðà÷ ñâÿçûâàåò ýòî ñ íèçêèì ðàñïîëîæåíèåì õîðèîíà – ñì. íèæå äàííûå ÓÇÈ). Ñ 23.08 ïî 29.08 èç-çà ýòèõ âûäåëåíèé ëåæàëà â ñòàöèîíàðå (1 óêîë äèöèíîíà è 2 óêîëà íî-øïû â ñóòêè), íî íè÷åãî íå èçìåíèëîñü. Ïîñëå îïðåäåëåíèÿ áåðåìåííîñòè ïðîêàïàëà ÷åòûðå êàïåëüíèöû ñ èììóíîãëîáóëèíîì.

Âîò ðîñò ÕÃ×:
14.08 – 627
20.08 – 11 088
27.08 – 57 351
31.08 – 75 821
03.09 – 105 315 ìÌÅ/ìë

Ïðîãåñòåðîí:
14.08 – 52,13
28.08 – 35,02 (ïðè ïðèåìå Óòðîæåñòàíà 2 ðàçà â ñóòêè ïî òàáëåòêå)
31.08 – 33,54
03.09 – 40,92 íã/ìë (ïîñëåäíèé ðåçóëüòàò ïðè ïðèåìå 6-òè òàáëåòîê Óòðîæåñòàíà â ñóòêè)

Ä-äèìåð óâåëè÷èëñÿ äî 100 íã/ìë

Òåñòîñòåðîí
28.08 – 56,74 íã/ìë

ÄÃÝÀ-Ñ
31.08 – 110,08 ìêã/ìë

17-ÎÍ ïðîãåñòåðîí
31.08 - 0,6 íã/ìë

ÓÇÈ 29.08:
Ñðåäíèé âíóòðåííèé äèàìåòð ïëîäíîãî ÿéöà 20 ìì
ÊÒÐ 7ìì, ñîîòâåòñòâóåò ìåíñòð. ñðîêó áåðåìåííîñòè
×ÑÑ ïëîäà – 128 óä/ìèí
Æåëòî÷íûé ìåøîê âèçóàëèçèðóåòñÿ, äèàìåòð – 3ìì
Ïðåèìóùåñòâåííîå ðàñïîëîæåíèå õîðèîíà ïî çàäíåé ñòåíêå ìàòêè, ïåðåêðûâàåò îáëàñòü âíóòðåííåãî çåâà. Ñòðóêòóðà õîðèîíà íå èçìåíåíà.
Ïî ïåðåäíåé ñòåíêå ìàòêè îïðåäåëÿåòñÿ ëîêàëüíîå óòîëùåíèå ìèîìåòðèÿ
Áåðåìåííîñòü 6-7 íåäåëü. Ãèïåðòîíóñ ìàòêè.

Ãåìîñòàçèîãðàììà îò 30.08: òðîìáîýëàñòîãðàììû È.Ò.Ï. - 13 (íîðìà 6-12 óñ.åä)
Àãðåãàöèÿ òðîìáîöèòîâ ÀÄÔ10 – 80% (íîðìà 50-75%), îñòàëüíûå ïîêàçàòåëè â íîðìå, íî äèàãíîç Ãèïåðôóíêöèÿ òðîìáîöèòîâ.

Àíòèòåëà ê ÕÃ×:
Èììóíîãëîáóëèíû
IgM îòðèöàò.8,0 (íîðìà äî 30 åä./ì)
IgG ïîëîæèò. 41 (íîðìà äî 25 åä./ì).

Ïðèíèìàþ
Óòðîæåñòàí (òðè ðàçà â äåíü ïî äâå êàïñóëû)
Ìàãíå-Á6 (òðè ðàçà â äåíü ïî òàáëåòêå)
Ïðåíàòàë Ôîðòå (ïî òàáëåòêå)
Ôîëèåâóþ êèñëîòó (2 òàáëåòêè ïî 0,001 ã)
Íà íî÷ü ñâå÷ó ñ ïàïàâåðèíîì,
Ïðè ïîòÿãèâàíèè æèâîòà – íî-øïó (äíåì òÿíåò ðåäêî, íåïðèÿòíûå îùóùåíèÿ â îñíîâíîì íî÷üþ).

Ïî ðåçóëüòàòó ãåìîñòàçèîãðàììû è àíòèòåë ê ÕÃ× âðà÷ äîïîëíèòåëüíî íàçíà÷èë Ìåòèïðåä (4 ìã â äåíü) è Êóðàíòèë (3 òàáëåòêè â äåíü).

Ñêàæèòå, ïîæàëóéñòà, äåéñòâèòåëüíî ëè ðåçóëüòàòû ãåìîñòàçèîãðàììû íàñòîëüêî ïëîõèå äëÿ ìîåãî ñðîêà áåðåìåííîñòè, ÷òî íóæíî ïðèíèìàòü Ìåòèïðåä è Êóðàíòèë. Ìîæåò áûòü ìîæíî îáîéòèñü áîëåå «ìÿãêèìè» ëåêàðñòâàìè?

×òî ÿ ìîãó åùå ñäåëàòü, ÷òîáû ñîõðàíèòü ýòó áåðåìåííîñòü? ×òî ïðîèñõîäèò ñ ïðîãåñòåðîíîì? Ïî÷åìó îí òàêîé íèçêèé ïðè ïîääåðæêå Óòðîæåñòàíîì?

ß î÷åíü âîëíóþñü, ò.ê. ñðîê ñåé÷àñ «êðèòè÷åñêèé», à âðà÷ ãîâîðèò, ÷òî è ýòà áåðåìåííîñòü ìîæåò îêàçàòüñÿ íåóäà÷íîé, ò.ê. ñåðäöåáèåíèå ïëîäà ðåäêîå, ïðîãåñòåðîí íèçêèé, èäóò âûäåëåíèÿ è ãåìîñòàç ïëîõîé.

Î÷åíü ïðîøó ïîìîùè óâàæàåìîãî ñîîáùåñòâà!
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 05.09.2006, 20:30
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,383
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íà ìîé âçãëÿä, èìåëî áû ñìûñë ïåðåïðîâåðèòü ãîìîöèñòåèí - íå ôàêò, ÷òî äàæå ïîñëå 2ìã ôîëèåâîé â ñóòêè îí îáÿçàòåëüíî ïðèäåò ê íîðìå, åñëè îñòàåòñÿ ïîâûøåííûì, òî óâåëè÷èòü ôîëèåâóþ äî 5 ìã è äîáàâèòü âèòàìèíû Â6 è öèàíîêîáàëàìèí. Ïîâûøåííûé ãîìîöèñòåèí ìîæåò áûòü îäíîé èç ïðè÷èí íåâûíàøèâàíèÿ. Íå ïîíÿòíî, ïî÷åìó óâåëè÷åíî âðåìÿ ðåêàëüöèôèêàöèè - åñòü ëè ïðåäïîëîæåíèÿ ìåäèêîâ â ýòîì ïëàíå èëè äîîáñëåäîâàíèÿ?, íàèáîëåå ÷àñòîé ïðè÷èíîé åãî óâåëè÷åíèÿ âñå æå ÿâëÿåòñÿ âîë÷àíî÷íûé àíòèêîàãóëÿíò â íèçêîì òèòðå, êñòàòè êàêèìè àíàëèçàìè èñêëþ÷àëè ïîñëåäíèé? Ïîâûøåíèå àãðåãàöèè òðîìáîöèòîâ ïðè áåðåìåííîñòè - íîðìàëüíûé ôèçèîëîãè÷åñêèé ïðîöåññ è íå òðåáóåò íàçíà÷åíèÿ äåçàãðåãàíòîâ (êóðàíòèëà).
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 05.09.2006, 21:22
Àëåêñàíäðà Ø. Àëåêñàíäðà Ø. âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 05.09.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 35
Ñêàçàë(à) ñïàñèáî: 13
Àëåêñàíäðà Ø. *
Öèòàòà:
Ñîîáùåíèå îò Dr. Vad
Íà ìîé âçãëÿä, èìåëî áû ñìûñë ïåðåïðîâåðèòü ãîìîöèñòåèí - íå ôàêò, ÷òî äàæå ïîñëå 2ìã ôîëèåâîé â ñóòêè îí îáÿçàòåëüíî ïðèäåò ê íîðìå, åñëè îñòàåòñÿ ïîâûøåííûì, òî óâåëè÷èòü ôîëèåâóþ äî 5 ìã è äîáàâèòü âèòàìèíû Â6 è öèàíîêîáàëàìèí. Ïîâûøåííûé ãîìîöèñòåèí ìîæåò áûòü îäíîé èç ïðè÷èí íåâûíàøèâàíèÿ. Íå ïîíÿòíî, ïî÷åìó óâåëè÷åíî âðåìÿ ðåêàëüöèôèêàöèè - åñòü ëè ïðåäïîëîæåíèÿ ìåäèêîâ â ýòîì ïëàíå èëè äîîáñëåäîâàíèÿ?, íàèáîëåå ÷àñòîé ïðè÷èíîé åãî óâåëè÷åíèÿ âñå æå ÿâëÿåòñÿ âîë÷àíî÷íûé àíòèêîàãóëÿíò â íèçêîì òèòðå, êñòàòè êàêèìè àíàëèçàìè èñêëþ÷àëè ïîñëåäíèé? Ïîâûøåíèå àãðåãàöèè òðîìáîöèòîâ ïðè áåðåìåííîñòè - íîðìàëüíûé ôèçèîëîãè÷åñêèé ïðîöåññ è íå òðåáóåò íàçíà÷åíèÿ äåçàãðåãàíòîâ (êóðàíòèëà).
Áîëüøîå ñïàñèáî çà îòâåò! Ãîìîöèñòåèí îáÿçàòåëüíî ïåðåñäàì. Ñåé÷àñ ïðèíèìàþ 10 ìã âèòàìèíà Â6 (â êîìïëåêñå Ïðåíàòàë). Ýòî ìàëî?

Ïî ïîâîäó ðåêàëüöèôèêàöèè íè÷åãî äîïîëíèòåëüíî íå ïðåäïðèíèìàëîñü. Âîò, òîëüêî ÷òî îáðàòèëà âíèìàíèå, ÷òî àíàëèç íà âîë÷. à/ê òîæå âêëþ÷àåò â ñåáÿ ýòîò ïàðàìåòð è çäåñü îí íîðìàëüíûé (ìàðò 2006 - ìåñÿö ñïóñòÿ ïîñëå ãåìîñòàçèîãðàììû, ãäå îí áûë ïîâûøåí):

Âîò àíàëèç íà âîë÷. à/ê:
dRvt - 27,3 (íîðìà <30)
dRvt (êîíòðîëü ñ íîðìàëüíîé ïëàçìîé) - 26,8
À×Ò - 33,9 (íîðìà 35-45)
À×Ò (êîíòðîëü ñ íîðìàëüíîé ïëàçìîé) - 37,1
Àêòèâèðîâàííîå âðåìÿ ðåêàëüöèôèêàöèè - 51,8 (íîðìà 50-70)
ÀÂÐ (êîíòðîëü ñ íîðìàëüíîé ïëàçìîé) 69,9
Ïðîòðîìáèíîâîå âðåìÿ ñ ðàçáàâëåííûì òðîìá - 48,5 (íîðìà <60)
ðÏ (êîíòðîëü ñ íîðìàëüíîé ïëàçìîé) 49,4
Âîë÷àíî÷íûé àê - íåò.

Åñëè ìîæíî, íàïèøèòå, ïîæàëóéñòà, Âàøå ìíåíèå ïî ïîâîäó ïðèåìà Ìåòèïðåäà â ìîåì ñëó÷àå.

Çàðàíåå ñïàñèáî!
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 05.09.2006, 21:45
silver silver âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.11.2005
Ãîðîä: Israel
Ñîîáùåíèé: 1,097
Ïîáëàãîäàðèëè 57 ðàç(à) çà 56 ñîîáùåíèé
silver ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsilver ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsilver ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsilver ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsilver ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsilver ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsilver ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsilver ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsilver ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsilver ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsilver ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Smile

çäðàâñòâóéòå
1 âëèÿíèå ãèïåðãîìîöèñòåèíåìèè íà âîçíèêíîâåíèå ïîâòîðíûõ âûêèäûøåé ñïîðíî
2ïîìèìî âîë÷àíî÷íîãî àíòèêîàãóëÿíòà ïðîâåðÿëèñü ëè àíòèêàðäèîëèïèíîâûå àíòèòåëà?
3 íå äóìàþ ÷òî äà÷à ìåòèïðåäà ÿâëÿþòñÿ îïðàâäàíîé
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 05.09.2006, 21:52
Àëåêñàíäðà Ø. Àëåêñàíäðà Ø. âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 05.09.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 35
Ñêàçàë(à) ñïàñèáî: 13
Àëåêñàíäðà Ø. *
Öèòàòà:
Ñîîáùåíèå îò silver
çäðàâñòâóéòå
1 âëèÿíèå ãèïåðãîìîöèñòåèíåìèè íà âîçíèêíîâåíèå ïîâòîðíûõ âûêèäûøåé ñïîðíî
2ïîìèìî âîë÷àíî÷íîãî àíòèêîàãóëÿíòà ïðîâåðÿëèñü ëè àíòèêàðäèîëèïèíîâûå àíòèòåëà?
3 íå äóìàþ ÷òî äà÷à ìåòèïðåäà ÿâëÿþòñÿ îïðàâäàíîé
ß ïðîâåðÿëà ñëåäóþùèå àíòèòåëà:
Àíòèêàðäèîëèïèí IgM (mPL) - 4
Àíòèêàðäèîëèïèí IgG (gPL) - 6,9
Àíòèòåëà ê äåíàòóðèðîâàííîé ÄÍÊ (ss) - 1,7
Àíòèòåëà ê íàòèâíîé ÄÍÊ (ds) - 0,1
Àíòèòåëà ê ìèêðîñîìàëüíîìó òèðåîèäíîìó àíòèãåíó - 30,9
Àíòèòåëà ê òèðåîãëîáóëèíó - 9
Àíòèòåëà ê ÔÐÍ - 0,6

Ïðî ïîâûøåííûå àíòèòåëà ê ÕÃ× ÿ ïèñàëà âûøå.

Áîëüøîå ñïàñèáî!
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 05.09.2006, 22:23
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,383
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò silver
çäðàâñòâóéòå
1 âëèÿíèå ãèïåðãîìîöèñòåèíåìèè íà âîçíèêíîâåíèå ïîâòîðíûõ âûêèäûøåé ñïîðíî
Çäðàâñòâóéòå,

Âîò äàííûå, íà êîòîðûå îïèðàþñü:

Pooled risk estimates of 2.7 (1.4 to 5.2) and 4.2 (2.0 to 8.8) were calculated for fasting and afterload plasma homocysteine concentrations, respectively. For the MTHFR T/T genotype a pooled risk estimate of 1.4 (1.0 to 2.0) was found. CONCLUSION(S): These data support hyperhomocysteinemia as a risk factor for recurrent early pregnancy loss. Further research should be focused on the pathophysiology of this relationship and on the clinical efficacy of B vitamin supplementation.

Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK.
Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis.
Fertil Steril. 2000 Dec;74(6):1196-9

Ýòî î ñâÿçè ãèïåðãîìîöèñòåèíåìèè è ïåðâè÷íîãî íåâûíàøèâàíèÿ:

Pregnancy loss was independently associated with positive lupus anticoagulant (matched odds ratio [OR], 2.6; 95% confidence interval [CI], 1.1-6.0), high levels of immunoglobulin M (IgM) antibodies against cardiolipin (OR for percentile 100 versus 0-80, 3.5; CI, 1.2-10.1) and against phosphatidylethanolamine (OR, 4.7; CI, 1.9-12.1), high levels of IgG antibodies against annexin V (OR, 3.2; CI, 1.1-9.1) and against tissue-type plasminogen activator (OR, 19.5; CI, 7.9-48.0), and high homocystinemia (OR, 4.1; CI, 1.3-12.5). A first early pregnancy loss is associated with increased levels of several autoantibodies and of homocysteine.

Gris JC, è ñîàâò.
Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study.
Blood. 2003 Nov 15;102(10):3504-13.

Ýòî ôðàíöóçñêèé îïûò ïèëîòíîé âèòàìèíîòåðàïèè ïðè ãèïåðãîìîöèñòåèíåìèè è íåâûíàøèâàíèè:

Twenty-five consecutive hyperhomocysteinemic patients, ages 20–37 years, who had no biological children were studied, each patient having 3–5 episodes between the eighth and sixteenth week of amenorrhea... showed a significant sex- and age-adjusted fasting total hyperhomocysteinemia (laboratory normal values for premenopausal women <12 μmol/L; [2]) in two consecutive blood samples. The 25 patients were homozygous for the 5,10 methylene tetrahydrofolate reductase (MTHFR) C677T allele.
We first tested the effect of a 1-month high-dose folic acid, 15 mg daily, and vitamin B6, 750 mg daily, treatment on homocysteine plasma concentrations. This work had been approved by our local Institutional Ethics Committee, and agreement was obtained from the institutional review board. Informed consent was obtained from all patients. A folic acid and vitamin B6 association was chosen because of a first successful pregnancy in our index patient [2] and because the vitamin B6 status of our patients was unknown. Preference was given to high doses in the absence of any consensus dose treatment. Most of the patients normalized their homocysteinemia, in this case, the same treatment was continued throughout the next pregnancy.
Twenty-two patients initiated a pregnancy during the 3-month period after the normalization of their homocysteinemia. Twenty patients were still pregnant after the sixteenth week of amenorrhea. No additional treatment was given. None of them developed gravidic hypertension, preeclampsia, elevated liver enzymes, low platelet syndrome, or abruptio placentae. All 20 pregnancies were successful with no evidence of any malformation. In the mothers, no abnormal bleeding was observed during delivery and they did not develop any clinically obvious thromboembolic complication. Premature birth occurred in four cases, with a nonsevere fetal growth retardation in two cases; postnatal evolution was good. Analysis of the placenta showed no evidence of abnormal vascular damage or tissue infarct.

Quere I, è ñîàâò.
Vitamin supplementation and pregnancy outcome in women with recurrent early pregnancy loss and hyperhomocysteinemia. Fertil Steril. 2001 Apr;75(4):823-5.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 05.09.2006, 22:48
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,383
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äà, âîë÷àíî÷íîãî àíòèêîàãóëÿíòà íåò, à âîò ïðè íèçêîì òèòðå àíòèêàðäèîëèïèíîâûõ àíòèòåë ðåêîìåíäóåòñÿ ïåðåïîâòîðèòü àíàëèç åùå ðàç, õîòÿ íåïîíÿòíî â òîé ëàáîðàòîðèè, ãäå äåëàëè, êàêèå çíà÷åíèÿ MPL è GPL ïðèíÿòû êàê íèçêèå (îáû÷íî 10-20), à êàêèå êàê îòðèöàòåëüíûå (ìåíåå 10). Åùå îïöèåé ìîæåò áûòü îöåíêà àíòèêàðäèîëèïèíîâîãî IgA èëè æå àíòèòåëà ê áåòà-2-ãëèêîïðîòåèíó-1, îñîáåííî åñëè åñòü âûñîêèé êëèí. ðèñê àíòîôîñôîëèïèäíîãî ñèíäðîìà è îòðèöàòåëüíûå àíòèêàðäèîëèï. è âîë÷àí. àíòèòåëà.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 06.09.2006, 10:50
Àëåêñàíäðà Ø. Àëåêñàíäðà Ø. âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 05.09.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 35
Ñêàçàë(à) ñïàñèáî: 13
Àëåêñàíäðà Ø. *
Öèòàòà:
Ñîîáùåíèå îò Dr. Vad
Äà, âîë÷àíî÷íîãî àíòèêîàãóëÿíòà íåò, à âîò ïðè íèçêîì òèòðå àíòèêàðäèîëèïèíîâûõ àíòèòåë ðåêîìåíäóåòñÿ ïåðåïîâòîðèòü àíàëèç åùå ðàç, õîòÿ íåïîíÿòíî â òîé ëàáîðàòîðèè, ãäå äåëàëè, êàêèå çíà÷åíèÿ MPL è GPL ïðèíÿòû êàê íèçêèå (îáû÷íî 10-20), à êàêèå êàê îòðèöàòåëüíûå (ìåíåå 10). Åùå îïöèåé ìîæåò áûòü îöåíêà àíòèêàðäèîëèïèíîâîãî IgA èëè æå àíòèòåëà ê áåòà-2-ãëèêîïðîòåèíó-1, îñîáåííî åñëè åñòü âûñîêèé êëèí. ðèñê àíòîôîñôîëèïèäíîãî ñèíäðîìà è îòðèöàòåëüíûå àíòèêàðäèîëèï. è âîë÷àí. àíòèòåëà.
Íîðìû ëàáîðàòîðèè
Àíòèêàðäèîëèïèí IgM ñë.ïîë. 10-23, ïîë. >23
Àíòèêàðäèîëèïèí IgG ñë.ïîë. 10-20, ïîë. >20

Ïîñòàðàþñü íàéòè, ãäå â Ìîñêâå äåëàþò àíòèêàðäèîëèïèí IgA è àíòèòåëà ê áåòà-2-ãëèêîïðîòåèíó-1.

Ñïàñèáî Âàì çà ñîâåòû!
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 12.09.2006, 17:50
Àëåêñàíäðà Ø. Àëåêñàíäðà Ø. âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 05.09.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 35
Ñêàçàë(à) ñïàñèáî: 13
Àëåêñàíäðà Ø. *
Ðåçóëüòàòû àíàëèçîâ

Ñåãîäíÿ ÿ ïîëó÷èëà ðåçóëüòàòû àíàëèçîâ, ñäàííûõ â 10.09.06.

Ãîìîöèñòåèí - 3,84 (íîðìà 5-10)

àíòèòåëà ê áåòà2ãëèêîïðîòåèíó1 IgG - 1,99
àíòèòåëà ê áåòà2ãëèêîïðîòåèíó 1 IgM - 1,07

Ïðîãåñòåðîí - 42,51 (íà 6-òè òàáëåòêàõ Óòðîæåñòàíà â ñóòêè)

ÕÃ× - 115 114,84

Óâàæàåìûå âðà÷è! Íå ìîãëè áû Âû îòâåòèòü, åñëè ýòî âîçìîæíî, íà ïàðó âîïðîñîâ, êîòîðûå âîçíèêëè ïîñëå ïîëó÷åíèÿ ðåçóëüòàòîâ:

Ïîñêîëüêó ïðåâûøåíèÿ ãîìîöèñòåèíà ñåé÷àñ íåò, íóæíî ëè ìíå ïðîäîëæàòü ïðèåì ôîëèåâîé êèñëîòû ïî 3 ìã èëè äîñòàòî÷íî äîçû, ñîäåðæàùåéñÿ â êîìïëåêñíûõ âèòàìèíàõ?

Ñ êàêîé íåäåëè áåðåìåííîñòè ÕÃ× ïåðåñòàåò ðîñòè? Âîëíóþñü,ò.ê. çà ïîñëåäíþþ íåäåëþ (ñ 3.09) âûðîñ òîëüêî íà 10 000 åä. Ñåé÷àñ ó ìåíÿ 8 íåäåëü, èäåò 9-ÿ.

Çàðàíåå áëàãîäàðíà çà îòâåòû.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 13:44.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.